pI: 6.9789 |
Length (AA): 885 |
MW (Da): 99522 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_128278)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G22980 | ribosomal protein S5/Elongation factor G/III/V family protein |
Babesia bovis | BBOV_IV003290 | Elongation factor Tu-like protein |
Brugia malayi | Bm1_18155 | Elongation factor Tu GTP binding domain containing protein |
Candida albicans | CaO19.11931 | translation elongation factor EF4 |
Candida albicans | CaO19.4451 | translation elongation factor EF4 |
Caenorhabditis elegans | CELE_K10C3.5 | Protein K10C3.5, isoform A |
Cryptosporidium hominis | Chro.60456 | elongation factor-like protein |
Cryptosporidium parvum | cgd6_3960 | elongation factor-like protein |
Dictyostelium discoideum | DDB_G0279689 | band 7 family protein |
Drosophila melanogaster | Dmel_CG33158 | CG33158 gene product from transcript CG33158-RB |
Echinococcus granulosus | EgrG_001009200 | elongation factor Tu GTP binding |
Entamoeba histolytica | EHI_155660 | Elongation factor 2, putative |
Echinococcus multilocularis | EmuJ_001009200 | elongation factor Tu GTP binding |
Homo sapiens | ENSG00000140598 | elongation factor Tu GTP binding domain containing 1 |
Leishmania braziliensis | LbrM.25.1640 | elongation factor 2-like protein |
Leishmania donovani | LdBPK_252160.1 | elongation factor 2-like protein |
Leishmania infantum | LinJ.25.2160 | elongation factor 2-like protein |
Leishmania major | LmjF.25.2080 | elongation factor 2-like protein |
Leishmania mexicana | LmxM.25.2080 | elongation factor 2-like protein |
Loa Loa (eye worm) | LOAG_05140 | hypothetical protein |
Mus musculus | ENSMUSG00000038563 | elongation factor Tu GTP binding domain containing 1 |
Neospora caninum | NCLIV_037640 | elongation factor Tu GTP-binding domain- containing protein, putative |
Oryza sativa | 4333588 | Os03g0650700 |
Oryza sativa | 4329604 | Os02g0543300 |
Onchocerca volvulus | OVOC11807 |
|
Plasmodium berghei | PBANKA_1361100 | elongation factor Tu, putative |
Plasmodium falciparum | PF3D7_1348300 | elongation factor Tu, putative |
Plasmodium knowlesi | PKNH_1252600 | elongation factor Tu, putative |
Plasmodium vivax | PVX_083310 | translation elongation factor, putative |
Plasmodium yoelii | PY02627 | Elongation factor Tu family, putative |
Saccharomyces cerevisiae | YNL163C | GTPase RIA1 |
Schistosoma japonicum | Sjp_0004390 | ko:K03234 elongation factor EF-2, putative |
Schistosoma japonicum | Sjp_0113280 | Elongation factor Tu GTP-binding domain-containing protein 1, putative |
Schistosoma mansoni | Smp_000110 | similar to elongation factor Tu GTP binding domain containing 1 isoform 6-related |
Schmidtea mediterranea | mk4.004643.00 | |
Schmidtea mediterranea | mk4.004204.01 | |
Trypanosoma brucei gambiense | Tbg972.3.2120 | translation elongation factor EF-2, putative |
Trypanosoma brucei | Tb927.3.2170 | translation elongation factor EF-2, putative |
Trypanosoma congolense | TcIL3000_3_1280 | translation elongation factor EF-2, putative |
Trypanosoma cruzi | TcCLB.504077.40 | translation elongation factor EF-2, putative |
Trypanosoma cruzi | TcCLB.507081.30 | translation elongation factor EF-2, putative |
Toxoplasma gondii | TGME49_268710 | elongation factor Tu GTP binding domain-containing protein |
Theileria parva | TP01_1088 | elongation factor Tu, putative |
Trichomonas vaginalis | TVAG_109490 | 116 kD U5 small nuclear ribonucleoprotein component, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.2170 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.2170 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.2170 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.3.2170 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
YNL163C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_1361100 | Plasmodium berghei | Essential | plasmo |
TGME49_268710 | Toxoplasma gondii | Probably essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.